# MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma

> **NCT04074564** · EARLY_PHASE1 · UNKNOWN · sponsor: **HRYZ Biotech Co.** · enrollment: 60 (estimated)

## Conditions studied

- Sarcoma

## Interventions

- **COMBINATION_PRODUCT:** MASCT-I, Camrelizumab,Apatinib

## Key facts

- **NCT ID:** NCT04074564
- **Lead sponsor:** HRYZ Biotech Co.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-22
- **Primary completion:** 2024-08-07
- **Final completion:** 2024-12-05
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04074564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04074564, "MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04074564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*